iCo Therapeutics Announces Poster Presentation at ARVO – Canada NewsWire (press release)

iCo Therapeutics Announces Poster Presentation at ARVO
Canada NewsWire (press release)
With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment